$1.02 Million in Sales Expected for Aethlon Medical, Inc. (NASDAQ:AEMD) This Quarter

Wall Street analysts expect Aethlon Medical, Inc. (NASDAQ:AEMDGet Rating) to report sales of $1.02 million for the current quarter, Zacks reports. Two analysts have provided estimates for Aethlon Medical’s earnings, with the lowest sales estimate coming in at $40,000.00 and the highest estimate coming in at $2.00 million. Aethlon Medical reported sales of $30,000.00 in the same quarter last year, which indicates a positive year over year growth rate of 3,300%. The company is expected to report its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that Aethlon Medical will report full-year sales of $1.46 million for the current year, with estimates ranging from $320,000.00 to $2.60 million. For the next financial year, analysts expect that the business will post sales of $95.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Aethlon Medical.

Several research analysts have commented on the stock. StockNews.com initiated coverage on shares of Aethlon Medical in a report on Saturday. They issued a “sell” rating for the company. Maxim Group cut their target price on shares of Aethlon Medical from $11.00 to $4.00 in a research note on Tuesday, February 15th.

Large investors have recently modified their holdings of the stock. Renaissance Technologies LLC raised its stake in shares of Aethlon Medical by 377.0% in the fourth quarter. Renaissance Technologies LLC now owns 242,200 shares of the medical equipment provider’s stock valued at $450,000 after acquiring an additional 191,425 shares during the period. Dimensional Fund Advisors LP bought a new position in Aethlon Medical during the 3rd quarter worth about $397,000. BlackRock Inc. grew its holdings in Aethlon Medical by 771.7% during the 3rd quarter. BlackRock Inc. now owns 73,074 shares of the medical equipment provider’s stock worth $282,000 after acquiring an additional 64,691 shares in the last quarter. Geode Capital Management LLC grew its holdings in Aethlon Medical by 32.3% during the 3rd quarter. Geode Capital Management LLC now owns 136,451 shares of the medical equipment provider’s stock worth $526,000 after acquiring an additional 33,330 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in shares of Aethlon Medical in the 3rd quarter valued at about $111,000. Hedge funds and other institutional investors own 10.58% of the company’s stock.

NASDAQ:AEMD opened at $1.61 on Tuesday. The firm has a market cap of $24.81 million, a price-to-earnings ratio of -2.68 and a beta of 0.81. Aethlon Medical has a 52 week low of $0.88 and a 52 week high of $12.49. The firm has a 50-day moving average price of $1.25 and a two-hundred day moving average price of $1.67.

About Aethlon Medical (Get Rating)

Aethlon Medical, Inc, a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.

See Also

Get a free copy of the Zacks research report on Aethlon Medical (AEMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.